In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Fate Therapeutics Inc (NASDAQ: FATE) was $4.79 for the day, down -4.96% from the previous closing price of $5.04. In other words, the price has decreased by -$4.96 from its previous closing price. On the day, 2.69 million shares were traded. FATE stock price reached its highest trading level at $5.11 during the session, while it also had its lowest trading level at $4.695.
Ratios:
Our analysis of FATE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
On January 24, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $115 to $7.
Wedbush Downgraded its Outperform to Neutral on January 06, 2023, whereas the target price for the stock was revised from $42 to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Dulac Edward J III sold 2,447 shares for $7.77 per share. The transaction valued at 19,013 led to the insider holds 101,479 shares of the business.
Dulac Edward J III sold 1,849 shares of FATE for $9,245 on Jan 29 ’24. The Chief Financial Officer now owns 103,926 shares after completing the transaction at $5.00 per share. On Jan 09 ’24, another insider, Wolchko J Scott, who serves as the President and CEO of the company, sold 14,391 shares for $4.37 each. As a result, the insider received 62,889 and left with 371,248 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 545020544 and an Enterprise Value of 263711664. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.58 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 4.151 whereas that against EBITDA is -1.655.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $1.63. The 50-Day Moving Average of the stock is -30.44%, while the 200-Day Moving Average is calculated to be 17.15%.
Shares Statistics:
FATE traded an average of 2.80M shares per day over the past three months and 2254800 shares per day over the past ten days. A total of 113.82M shares are outstanding, with a floating share count of 99.49M. Insiders hold about 12.59% of the company’s shares, while institutions hold 90.58% stake in the company. Shares short for FATE as of 1711584000 were 16485200 with a Short Ratio of 5.89, compared to 1709164800 on 13490870. Therefore, it implies a Short% of Shares Outstanding of 16485200 and a Short% of Float of 17.899999.
Earnings Estimates
The stock of Fate Therapeutics Inc (FATE) is currently in the spotlight, with RATE analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $37.42, with high estimates of $4.79 and low estimates of $7.23.
